<DOC>
	<DOCNO>NCT01170052</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability activity combination bendamustine rituximab patient relapsed/refractory mantle cell lymphoma eligible high dose chemotherapy autologous/allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Bendamustine Temsirolimus Patients With Relapsed Refractory Mantle Cell Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Age 18 year old Mantle Cell Lymphoma accord REAL/WHO classification First second relapse alternatively progression therapy . Previous use Bendamustine permit , patient reach least partial remission progression occur 6 month therapy . Previous high dose chemotherapy autoSCT permit , patient reach least partial remission progression occur 12 month therapy . Patients must eligible high dose chemotherapy autoSCT alloSCT . Adequate bone marrow function ( hemoglobin &gt; 9g/dl , platelet count &gt; 100/nL , absolute neutrophil count &gt; 1,5 /nL ) WHO/ECOG Performance Status 02 Measurable disease ( two perpendicular diameter either physical radiological examination ) Life expectancy â‰¥ 3 week Written inform consent Prior treatment mTOR Inhibitor Unstable severe uncontrolled medical condition ( e.g . severe congestive heart failure , myocardial infarction within past 6 month , severe , uncontrolled arterial hypertension , renal insufficiency require hemodialysis , severe pulmonary disease , severe diabetes ) Abnormal liver function : transaminase total bilirubin &gt; 2 x upper limit normal ( ULN ) Abnormal renal function : serum creatinine &gt; 2 x upper limit normal Previous malignancy nonmelanoma skin cancer carcinoma situ cervix . Concurrent treatment strong inhibitor CYP3A4 and/or inducer CYP3A4 Pregnant breastfeed woman ( negative pregnancy test old 7 day require woman fertile age ) . Men woman childbearing potential must agree use adequate contraception ( i.e . failure rate &lt; 1 % p.a . ) Major surgery within 4 week study entry ; minor procedure ( e.g . Implantation i.v . port catheter , Lymphnode biopsy ) within 1 week study entry Previous therapy investigational agent within 28 day study entry Concomitant immunotherapy ( e.g . Rituximab ) Chemotherapy Bendamustine . Use systemic steroid document Principal Investigator inform . Central nervous system ( CNS ) lymphomatous involvement HIV positivity Current chronic hepatitis B hepatitis C infection Severe psychiatric illness Individuals place institution due magisterial judiciary command . Inability comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Relapsed Mantle Cell Lymphoma</keyword>
	<keyword>Refractory Mantle Cell Lymphoma</keyword>
	<keyword>Non-Hodgkins Lymphoma</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Bendamustine</keyword>
	<keyword>Phase 1/2</keyword>
</DOC>